<?xml version="1.0" encoding="UTF-8"?>
<p>The first line of treatment for patients presented with the symptoms of COVID-19 (fever, dry cough, and shortness of breath) is self-quarantine for at least 14 days. Cases are monitored for progression of symptoms such as increased fever (&gt;40°C), significant difficulty breathing or shortness of breath, mouth breaks, constant coughing, and dehydration. If there is no significant improvement in symptoms, it is advisable to consult a clinician for confirmation of the diagnosis and to avoid further spread of the virus. The main treatment currently available is supportive care. Although there is limited information on COVID-19, it has been linked to ARDS. For patients with high fevers that could potentially lead to dehydration, intravenous fluids such as normal saline or lactated Ringer’s fluid can be administered sparingly to prevent lung overload. To reduce fever, antipyretic drugs such as paracetamol or acetaminophen can be administered. Drugs such as remdesivir, chloroquine, ritonavir, tocilizumab, corticosteroids have been repurposed for the treatment of COVID-19 (
 <xref ref-type="fig" rid="fig11-0300060520949077">Figure 11</xref>), although their clinical effectiveness has not yet been confirmed.
 <sup>
  <xref rid="bibr88-0300060520949077" ref-type="bibr">88</xref>
  <xref rid="bibr89-0300060520949077" ref-type="bibr"/>
  <xref rid="bibr90-0300060520949077" ref-type="bibr"/>
  <xref rid="bibr91-0300060520949077" ref-type="bibr"/>
  <xref rid="bibr92-0300060520949077" ref-type="bibr"/>–
  <xref rid="bibr93-0300060520949077" ref-type="bibr">93</xref>
 </sup> Unfortunately, the use of chloroquine and derivatives such as hydroxychloroquine, alone or in combination with other drugs, resulted in cardiac toxicity. Investigations of these drugs were recently suspended by the WHO.
 <sup>
  <xref rid="bibr94-0300060520949077" ref-type="bibr">94</xref>
 </sup>
</p>
